home / stock / pulm / pulm quote
Last: | $2.0201 |
---|---|
Change Percent: | -0.49% |
Open: | $2.03 |
Close: | $2.0201 |
High: | $2.052 |
Low: | $2.0201 |
Volume: | 4,089 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.0201 | $2.03 | $2.0201 | $2.052 | $2.0201 | 4,089 | 04-24-2024 |
$2.0201 | $2.07 | $2.0201 | $2.09 | $2.0201 | 790 | 04-23-2024 |
$2.015 | $2.0136 | $2.015 | $2.015 | $1.94 | 8,481 | 04-22-2024 |
$1.9897 | $2.0294 | $1.9897 | $2.04 | $1.91 | 11,955 | 04-19-2024 |
$1.96 | $2.06 | $1.96 | $2.09 | $1.91 | 31,035 | 04-18-2024 |
$2.09 | $2.08 | $2.09 | $2.11 | $2.0594 | 3,684 | 04-17-2024 |
$2.12 | $2.08 | $2.12 | $2.19 | $2.08 | 6,129 | 04-16-2024 |
$2.09 | $2.16 | $2.09 | $2.18 | $2.08 | 5,271 | 04-15-2024 |
$2.16 | $2.141 | $2.16 | $2.19 | $2.05 | 26,202 | 04-12-2024 |
$2.1 | $1.95 | $2.1 | $2.15 | $1.95 | 62,527 | 04-11-2024 |
$1.9 | $1.82 | $1.9 | $1.99 | $1.8 | 18,565 | 04-10-2024 |
$1.91 | $1.94 | $1.91 | $1.94 | $1.8601 | 1,900 | 04-09-2024 |
$1.89 | $1.99 | $1.89 | $2.03 | $1.89 | 16,562 | 04-08-2024 |
$2.009 | $1.7262 | $2.009 | $2.06 | $1.7262 | 88,038 | 04-05-2024 |
$1.8784 | $1.8 | $1.8784 | $1.93 | $1.8 | 35,588 | 04-04-2024 |
$1.81 | $1.775 | $1.81 | $1.8656 | $1.765 | 5,296 | 04-03-2024 |
$1.71 | $1.75 | $1.71 | $1.75 | $1.68 | 3,278 | 04-02-2024 |
$1.74 | $1.7 | $1.74 | $1.8 | $1.7 | 8,462 | 04-01-2024 |
$1.75 | $1.65 | $1.75 | $1.85 | $1.5601 | 39,041 | 03-29-2024 |
$1.75 | $1.65 | $1.75 | $1.85 | $1.5601 | 39,041 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cipla partnership resulted in the wind down o...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire Cipla to take sole responsibility for development of PUR1900, refocu...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline...